Single-Cell Profiling Defines Transcriptomic Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4⁺ T...

Area of Science:

• Immunology
• Oncology
• Computational Biology

Background:

• Current cancer immunotherapies primarily focus on cytotoxic CD8+ T cells.
• CD4+ tumor-infiltrating lymphocytes (TILs) show clinical promise, but their functional heterogeneity complicates therapeutic strategies.
• Understanding the specific roles and states of CD4+ TILs is crucial for advancing cancer treatment.

Purpose of the Study:

• To characterize the transcriptomic landscape and functional programs of tumor-specific CD4+ T cells within the tumor microenvironment.
• To compare CD4+ TIL responses with those in draining lymph nodes (dLNs) and known anti-viral responses.
• To identify potential therapeutic targets within CD4+ TIL populations for improved cancer immunotherapy.

Main Methods:

• Single-cell mRNA sequencing was employed to analyze CD4+ TILs and dLN T cells from tumor-bearing models.
• Computational methods were utilized to identify and classify distinct T cell subpopulations based on their transcriptomic profiles.
• Type I interferon signatures in TILs were identified and correlated with clinical data from human cancer patients.

Main Results:

• Tumor-specific CD4+ TILs exhibit unique transcriptomic patterns, differing significantly from acute/chronic anti-viral responses.
• A notable diversity was observed among T-bet-expressing T helper type 1 (Th1)-like TILs.
• dLN T cell responses included T follicular helper (Tfh) cells but lacked Th1 cells, suggesting compartmentalized immune activity.
• A type I interferon-driven signature was identified in Th1-like TILs and found to be negatively associated with checkpoint therapy response in human cancers.

Conclusions:

• CD4+ T cell populations within tumors possess distinct effector programs that differ from systemic immune responses.
• The identified type I interferon signature in Th1-like TILs represents a potential biomarker for immunotherapy response and a target for intervention.
• This study provides a foundational methodology for dissecting CD4+ T cell functions in cancer and offers new avenues for enhancing immunotherapy strategies.